FDA de­lays de­ci­sion on GSK blood can­cer drug at heart of $1.9B Sier­ra On­col­o­gy deal

GSK’s blood can­cer drug mo­melo­tinib has tak­en an­oth­er turn on its wind­ing jour­ney, with the FDA de­lay­ing its re­view of the in­ves­ti­ga­tion­al tablet that GSK picked up in last year’s buy­out of Sier­ra On­col­o­gy by three months.

GSK said Fri­day that the reg­u­la­tor pushed back its de­ci­sion, orig­i­nal­ly slat­ed for June 16, to Sept. 16, to “pro­vide time to re­view re­cent­ly sub­mit­ted da­ta.”

“GSK is con­fi­dent in the mo­melo­tinib NDA and looks for­ward to work­ing with the FDA as they fi­nal­ize their re­view,” the com­pa­ny said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER